Abstract:Combination therapy for tumors can play a synergistic role while leveraging their respective therapeutic advantages, but there are still some challenges in the development of nanomaterials for multimodal combination therapy for tumors. In this study, a novel targeted nanoparticle drug delivery platform (HMPDA@Ce6/DOX@AMC) based on hollow mesoporous polydopamine (HMPDA) was designed for synergistic treatment of tumors. HMPDA with cavity structure were used to load the anticancer drug doxorubicin hydrochloride (DOX) and the photosensitizer Chlorin e6 (Ce6). In the acidic tumor microenvironment, under the irradiation with 660 nm laser, the carrier would release Ce6 and DOX in a rapid response, while producing cytotoxic reactive oxygen species (ROS). Then, the immunomodulator CpG, the anti-cancer gene miR-145 and S6-Aptamer were linked, which were named AMC. S6-Aptamer was used for chemotherapy drugs to accurately target cancer cells, and CPG was used for immunotherapy (IMT) by enhancing anti-tumor immune response. It was found that the average loading of DOX on nanocarriers reached 242.65 mg/g. Using the indicator 1, 3-diphenylisobenzofuran (DPBF), it was detected that the prepared nanocarriers could produce ROS under the irradiation of a specific wavelength of laser, and the yield was positively correlated with the irradiation time. The cytotoxicity experiments showed that the nanocarriers had obvious inhibitory effect on 4T1 cells. The designed nano drug delivery system had stronger tumor inhibition ability than single therapy under the combination of multiple therapies, and is expected to achieve accurate targeting and enhanced treatment of early tumors.

Homologous polydopamine ameliorates haemolysis of melittin for enhancing its anticancer efficacy

Bottlebrush Polymer-Conjugated Melittin Exhibits Enhanced Antitumor Activity and Better Safety Profile

Metal–Phenolic Network-Facilitated “Foe-to-Friend” Conversion of Melittin for Cancer Immunotherapy with Boosted Abscopal Effect

Genetically engineered nano-melittin vesicles for multimodal synergetic cancer therapy

Selective Inhibition of Cancer Cells by Enzyme-Induced Gain of Function of Phosphorylated Melittin Analogues.

Turning Toxicants into Safe Therapeutic Drugs: Cytolytic Peptide−Photosensitizer Assemblies for Optimized In Vivo Delivery of Melittin

Highly Effective Photothermal Chemotherapy with Ph-Responsive Polymer-Coated Drug-Loaded Melanin-Like Nanoparticles

Delivery of melarsoprol using folate-targeted PEGylated cyclodextrin-based nanoparticles for hepatocellular carcinoma

Graphene Oxide-Based Magnetic Nanocomposites for the Delivery of Melittin to Cervical Cancer HeLa Cells.

Polydopamine surface-modified hyperbranched polymeric nanoparticles for synergistic chemo/photothermal therapy of oral cancer

Homologous-targeting biomimetic nanoparticles co-loaded with melittin and a photosensitizer for the combination therapy of triple negative breast cancer

One-step and facile synthesis of peptide-like poly(melphalan) nanodrug for cancer therapy

NIR Enhanced pH‐Responsive Microneedles for Synergetic Therapy of Melanoma

Boronophenylalanine‐Containing Polydopamine Nanoparticles for Enhanced Combined Boron Neutron Capture Therapy and Photothermal Therapy for Melanoma Treatment

Rgd-Modified Lipid Disks As Drug Carriers for Tumor Targeted Drug Delivery

Recent advances in melittin-based nanoparticles for antitumor treatment: from mechanisms to targeted delivery strategies

Synergistic Therapy of Melanoma by Co-Delivery of Dacarbazine and Ferroptosis-Inducing Ursolic Acid Using Biomimetic Nanoparticles

Study on the application of hollow mesoporous polydopamine as nanoparticle drug carrier in tumor combination therapy

Melittin-incorporated nanomedicines for enhanced cancer immunotherapy

Co-delivery of Homoharringtonine and Doxorubicin Boosts Therapeutic Efficacy of Refractory Acute Myeloid Leukemia

Engineering Bio-MOF/polydopamine as a biocompatible targeted theranostic system for synergistic multi-drug chemo-photothermal therapy